Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- , as therapy for previously treated indolent non-Hodgkin lymphoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- , as therapy for previously treated indolent non-Hodgkin lymphoma
Authors
Keywords
-
Journal
BLOOD
Volume 123, Issue 22, Pages 3406-3413
Publisher
American Society of Hematology
Online
2014-03-11
DOI
10.1182/blood-2013-11-538546
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Management of indolent lymphoma: Where are we now and where are we going
- (2012) Matthew A. Lunning et al. BLOOD REVIEWS
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Non-Hodgkin lymphoma
- (2012) Kate R Shankland et al. LANCET
- PI3K signalling: the path to discovery and understanding
- (2012) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The role of phosphatidylinositol 3-kinase- in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia
- (2011) S. E. M. Herman et al. BLOOD
- The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
- (2011) J. Hoellenriegel et al. BLOOD
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- I-131 tositumomab
- (2010) Basem M William et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- The emerging mechanisms of isoform-specific PI3K signalling
- (2010) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma
- (2009) N. Di Bella et al. BLOOD
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- Bendamustine: Rebirth of an Old Drug
- (2009) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
- (2009) Thomas E. Witzig et al. JOURNAL OF CLINICAL ONCOLOGY
- Phosphoinositide 3-Kinase p110 Regulates Natural Antibody Production, Marginal Zone and B-1 B Cell Function, and Autoantibody Responses
- (2009) C. A. Durand et al. JOURNAL OF IMMUNOLOGY
- A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma
- (2008) Arturo Molina Annual Review of Medicine
- Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study
- (2008) Jonathan W. Friedberg et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search